<h6>Table 4: Ten new BioBrick™ of anticancer peptides designed by our team</h6>
<br>
<h4><i>ii) Building the construction</i></h4>
<p>All ACP inserts have been incorporated into our pET plasmid and then was tranformed into DH5alpha for cloning. Next, colony PCR would be conducted to check the plasmid. Three out of ten pET-ACP plasmids got the positive results (ACP1, ACP5 and C-rds-CPP) and proceed to the next step: protein expression and purification. </p>
<p>All ACP inserts have been incorporated into our pET plasmid and then was tranformed into DH5alpha for cloning. Next, colony PCR would be conducted to check the plasmid. Three out of ten pET-ACP plasmids got the positive results (ACP1, ACP5 and C-rds-CPP) and were transformed into BL21 to proceed to the next step: protein expression and purification. </p>
<br>
<h4><i>iii) Testing the anticancer effect to A549 cell line</i></h4>
<p>The experimental data showed that the ACPs from <i>Cordyceps militaris</i> (C-ori, C-rds, C-rds-CPP) are less effective at killing A549 compared with ACP1 and ACP5 (KAPI). At concentration of 50µM, all peptide drug, except ACP5 (KAPI), has no significant effects compared to the control. </p>
